Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9541.0411
Address
Unit 4 1 The Crescent Kingsgrove, New South Wales (NSW) 2208
Description
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. It operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.35 - 3.15
Trade Value (12mth)
AU$24,290.00
1 week
3.7%
1 month
0%
YTD
-26.7%
1 year
-41.67%
All time high
3.45
EPS 3 yr Growth
-35.70%
EBITDA Margin
-33.20%
Operating Cashflow
-$7m
Free Cash Flow Return
-18.60%
ROIC
-12.20%
Interest Coverage
-40.50
Quick Ratio
2.30
Shares on Issue (Fully Dilluted)
96m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
03 September 24 |
Cyclopharm - 2024 First Half Results & USA Expansion Update
×
Cyclopharm - 2024 First Half Results & USA Expansion Update |
29 August 24 |
Webinar - 1H2024 Results and USA update
×
Webinar - 1H2024 Results and USA update |
27 August 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
27 August 24 |
Cyclopharm 2024 H1 Trading and USA Expansion Update
×
Cyclopharm 2024 H1 Trading and USA Expansion Update |
28 June 24 |
Application for quotation of securities - CYC
×
Application for quotation of securities - CYC |
28 June 24 |
Change of Director's Interest Notice - DH
×
Change of Director's Interest Notice - DH |
28 June 24 |
Change of Director's Interest Notice - DA
×
Change of Director's Interest Notice - DA |
28 June 24 |
Change of Director's Interest Notice - KB
×
Change of Director's Interest Notice - KB |
28 June 24 |
Proposed issue of securities - CYC
×
Proposed issue of securities - CYC |
28 June 24 |
Application for quotation of securities - CYC
×
Application for quotation of securities - CYC |
28 June 24 |
Cleansing Notice
×
Cleansing Notice |
27 June 24 |
Update - Proposed issue of securities - CYC
×
Update - Proposed issue of securities - CYC |
27 June 24 |
Appendix 3B
×
Appendix 3B |
25 June 24 |
Cyclopharm completes oversubscribed Share Purchase Plan
×
Cyclopharm completes oversubscribed Share Purchase Plan |
25 June 24 |
Update - Proposed issue of securities - CYC
×
Update - Proposed issue of securities - CYC |
24 June 24 |
USA Reimbursement Update for TECHNEGAS
×
USA Reimbursement Update for TECHNEGAS |
19 June 24 |
Cyclopharm Presenting at Macquarie Emerging Leaders Conf
×
Cyclopharm Presenting at Macquarie Emerging Leaders Conf |
11 June 24 |
Change in substantial holding Barings
×
Change in substantial holding Barings |
11 June 24 |
Change in substantial holding Chemical Overseas
×
Change in substantial holding Chemical Overseas |
11 June 24 |
Change in substantial holding AACCF
×
Change in substantial holding AACCF |
05 June 24 |
TECHNEGAS Awarded US Pass-Through Reimbursemt Status
×
TECHNEGAS Awarded US Pass-Through Reimbursemt Status |
05 June 24 |
Change in substantial holding from CVC
×
Change in substantial holding from CVC |
04 June 24 |
CYC Results of AGM Poll - Addendum
×
CYC Results of AGM Poll - Addendum |
04 June 24 |
Update - Application for quotation of securities - CYC
×
Update - Application for quotation of securities - CYC |
04 June 24 |
Cleansing Statement - Placement
×
Cleansing Statement - Placement |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.